内容概况：近年来，中国傅立叶红外光谱仪行业在技术水平上取得了显著进步。国内企业通过自主研发 和技术创新，逐步突破了干涉仪、光源、检测器等关键部件的技术壁垒，部分产品已达到国际先进水 平。2024年，中国傅立叶红外光谱仪市场规模达18.24亿元，同比增长9.75%。随着环保法规趋严、生物 医药研发投入增加，以及新能源材料需求爆发，傅立叶红外光谱仪的应用场景将持续扩大。 相关上市企业：聚光科技（300203） 相关企业：福晶科技股份有限公司、奥普光电股份有限公司、光库科技股份有限公司、杰普特光电股份 有限公司、华测检测认证集团股份有限公司、广电计量检测股份有限公司、锐科光纤激光器技术有限责 任公司、炬光科技股份有限公司、德龙激光股份有限公司、英诺激光科技股份有限公司、北京北分瑞利 分析仪器（集团）有限责任公司、北京普析通用仪器有限责任公司、上海仪电分析仪器有限公司、华兰 生物工程股份有限公司、智飞生物技术股份有限公司 关键词：傅立叶红外光谱仪、傅立叶红外光谱仪市场规模、傅立叶红外光谱仪行业现状、傅立叶红外光 谱仪发展趋势 一、行业概述 傅里叶变换红外光谱仪（Fourier Transform Infrared S ...

Core Viewpoint - After being acquired by Midea Group for four years, Wandong Medical has undergone a leadership change, with Hu Ziqiang resigning as chairman and being succeeded by Ma Chibing, both of whom are Midea Group executives [2][3]. Group 1: Leadership Changes - Hu Ziqiang has resigned from his positions at Wandong Medical due to personal reasons, effective immediately, and will no longer hold any roles within the company [2]. - Ma Chibing, who has over 20 years of experience at Midea Group, has been appointed as the new chairman of Wandong Medical [2][3]. - Hu Ziqiang previously served as Midea Group's Vice President and CTO, while Ma Chibing has held various leadership roles within Midea, including overseeing the cleaning appliance division [3]. Group 2: Financial Performance - In 2024, Wandong Medical reported a revenue of 1.524 billion yuan, marking a 23.26% year-on-year increase, the largest revenue growth in the past decade [6]. - Despite the revenue growth, the company's net profit attributable to shareholders decreased by 16.54% to 157 million yuan in 2024, following a trend of declining net profits over the past three years [6]. - The company has experienced a decline in gross profit margin each year, with costs increasing significantly, particularly in the context of a shift towards higher-end products [6][7]. Group 3: Market Strategy - Wandong Medical is focusing on expanding into the mid-to-high-end market, with a strategic plan to strengthen its domestic foundation while also targeting international markets [6]. - The company has established a "5+1" regional layout for overseas markets, achieving a revenue of 233 million yuan from international sales, which represents a 68.36% increase year-on-year [7]. - However, the costs associated with this international expansion have risen sharply, with a 108.38% increase in corresponding costs, leading to a decrease in gross margin [7].